Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.
about
Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitorPhase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancersVascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularizationStructural and functional properties of platelet-derived growth factor and stem cell factor receptorsMagnetic resonance perfusion imaging in neuro-oncology.Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment.A current review of targeted therapeutics for ovarian cancer.Enhancing fraction measured using dynamic contrast-enhanced MRI predicts disease-free survival in patients with carcinoma of the cervix.Targeting the PDGF signaling pathway in the treatment of non-malignant diseases.Targeting the PDGF signaling pathway in tumor treatmentA phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumorsBreast tumor microenvironment: proteomics highlights the treatments targeting secretome.Phase I study of olaratumab in Japanese patients with advanced solid tumors.CRSBP-1/LYVE-l-null mice exhibit identifiable morphological and functional alterations of lymphatic capillary vessels.The merits of vascular targeting for gynecologic malignancies.Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging.Review of the pericyte during angiogenesis and its role in cancer and diabetic retinopathy.DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.Novel agents in ovarian cancer.Antiangiogenic drugs in ovarian cancer.The role of clinical imaging in oncological drug development.Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?Opportunities and pitfalls of cancer imaging in clinical trials.Modulating antibody pharmacokinetics using hydrophilic polymers.Novel targets for VEGF-independent anti-angiogenic drugs.Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging.Mechanisms of age-related macular degeneration and therapeutic opportunities.PDGF and the progression of renal disease.Platelet-derived growth factor signaling in the lung. From lung development and disease to clinical studies.Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies.Olaratumab for the treatment of soft-tissue sarcoma.Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report.Prediction of therapy response in ovarian cancer: Where are we now?Tumor angiogenesis and vascular normalization: alternative therapeutic targets.Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report.
P2860
Q24594930-B83CCDDB-7879-4BFD-BF68-726B59B6DF2FQ24644683-39089318-BE47-410D-8E38-FED2418352B3Q26781833-6AD92A47-BF3A-4354-B8D5-F1E530077EEAQ26829546-6B9383FF-C966-481E-B48B-3C6095BDAE0CQ30479156-3006661F-BE87-48AF-99EE-CB792FAA4BDBQ33401360-CE0E153F-1811-4B9E-9D52-74D5ADFF284AQ33408049-CE0C2756-C04E-4792-9D8C-2E674BCBDE88Q33427833-61A98432-2911-4B79-9975-DA4586218936Q33580998-556085B0-E631-4B03-A399-3BA4FB0879B4Q33620142-04C384C1-6E98-4930-8224-33419C55F799Q34352802-0132C464-4BF7-475C-88ED-11828403A740Q34393461-6562548A-31FC-456B-810F-49F3A3F1F306Q34403375-D1974167-AE47-4BE0-A13B-DBC114212042Q34759911-EA9A694D-360F-4914-A4E6-76212ED56AAAQ35051852-5DBFF580-1641-437F-98D7-55098145BF1BQ35073422-9289CF78-8C90-4BD0-BE71-9CB0DD36743CQ35116734-D54D11DF-CAE1-4234-8E86-0BB9ECE17581Q35867576-B748B26E-5123-4799-82B8-B3727D279C85Q36680668-9497D0A4-91BA-4A14-9A9E-295BE1B169FEQ36702766-46E06242-9A56-41F8-95AA-3EB87F8F2B83Q36822880-FB0C3DE7-DC68-4EF5-9E6A-CCE9B6270759Q36872284-74E9DF39-2BC6-4850-8239-509D4D92E8C3Q36904860-B303BC93-94BE-4A33-98E0-2E1B233813BAQ37080913-3B60DD3D-BFA8-4DE3-BD00-C995C97E7C1EQ37187098-277EB635-C529-44E5-B86D-820499683DE2Q37498272-E108671E-99BC-448F-9B58-59F3687FEFAFQ37846342-6BD2D3DB-8FBC-41D1-9F8B-073443CEF359Q37869334-69DA2403-FE91-4C21-9207-45DDADF7C8BFQ37919888-72330FCA-E78A-441C-AEDD-3B17556BC0D9Q37984612-EFE91317-2D66-4BF2-92E3-BBAEE05F2B58Q38007857-1A3C47D0-5A1B-4220-810C-B51983B4EB11Q38150757-106DC11E-484F-4259-A709-B7166B52721EQ38185014-9834AFCA-84C7-4DB0-A9EB-0FF03328B0FCQ38258904-9FDF15A4-A7F4-4B72-8078-66C5E5DDD6EBQ38261599-34E7491C-0C0E-44DB-B9F5-FB56EB2FD225Q38651664-6FF00F38-0DFF-4712-964F-46F276EF1F7AQ39070963-A16E3A5E-2C08-40C2-866D-52E7BC73C91BQ39263260-C9A63D15-BF93-4BC6-99CC-0E265B49ED19Q39403862-2C296855-FA15-42AD-879C-49BF9903E349Q40229471-DC829A78-2F5E-4D24-AA24-7414C42C55FF
P2860
Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Blockade of platelet-derived g ...... sed tumor vascularized volume.
@en
type
label
Blockade of platelet-derived g ...... sed tumor vascularized volume.
@en
prefLabel
Blockade of platelet-derived g ...... sed tumor vascularized volume.
@en
P2093
P50
P356
P1476
Blockade of platelet-derived g ...... ased tumor vascularized volume
@en
P2093
Broughton L
Carrington B
Lawrance J
Mullamitha S
Saunders M
P304
P356
10.1200/JCO.2005.01.032
P407
P577
2004-10-04T00:00:00Z